| Joseph Choi, | |
|
2000 W Bethany Home Rd, Phoenix, AZ 85015-2443 | |
| (602) 249-0212 | |
| Not Available |
| Full Name | Joseph Choi |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 8 Years |
| Location | 2000 W Bethany Home Rd, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003266792 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 64771 (Arizona) | Secondary |
| 207P00000X | Emergency Medicine | MD470300 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abrazo West Campus | Goodyear, AZ | Hospital |
| Abrazo Scottsdale Campus | Phoenix, AZ | Hospital |
| Arrowhead Hospital | Glendale, AZ | Hospital |
| Abrazo Central Campus | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Group Of Arizona Professional Corporation | 1355596644 | 67 |
| Honorhealth | 1456258607 | 45 |
News Archive
Men's Health Network is pleased to announce the formation of a Men's Health Caucus in official relations with the American Public Health Association. As an active participant of the APHA Annual Meeting for many years we have seen growing interest and excitement generated around the need and desire to form a Men's Health Caucus and we are happy to see it come to fruition.
Health officials attending last week's World Health Assembly "failed to come to an agreement on a binding convention on stimulating research and development [R&D] focusing on the health problems of developing countries," BMJ reports.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.
Genevac reports customer paper describing development of a new evaporative methods for Mass Spec analysis replacing the traditional Solid Phase Extraction tech.
› Verified 5 days ago
| Entity Name | Honorhealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801092564 PECOS PAC ID: 1456258607 Enrollment ID: O20031216000350 |
News Archive
Men's Health Network is pleased to announce the formation of a Men's Health Caucus in official relations with the American Public Health Association. As an active participant of the APHA Annual Meeting for many years we have seen growing interest and excitement generated around the need and desire to form a Men's Health Caucus and we are happy to see it come to fruition.
Health officials attending last week's World Health Assembly "failed to come to an agreement on a binding convention on stimulating research and development [R&D] focusing on the health problems of developing countries," BMJ reports.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.
Genevac reports customer paper describing development of a new evaporative methods for Mass Spec analysis replacing the traditional Solid Phase Extraction tech.
› Verified 5 days ago
| Entity Name | Emcare - Pnx Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902855992 PECOS PAC ID: 3779574165 Enrollment ID: O20040524000667 |
News Archive
Men's Health Network is pleased to announce the formation of a Men's Health Caucus in official relations with the American Public Health Association. As an active participant of the APHA Annual Meeting for many years we have seen growing interest and excitement generated around the need and desire to form a Men's Health Caucus and we are happy to see it come to fruition.
Health officials attending last week's World Health Assembly "failed to come to an agreement on a binding convention on stimulating research and development [R&D] focusing on the health problems of developing countries," BMJ reports.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.
Genevac reports customer paper describing development of a new evaporative methods for Mass Spec analysis replacing the traditional Solid Phase Extraction tech.
› Verified 5 days ago
| Entity Name | Emergency Group Of Arizona Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215275433 PECOS PAC ID: 1355596644 Enrollment ID: O20130313000442 |
News Archive
Men's Health Network is pleased to announce the formation of a Men's Health Caucus in official relations with the American Public Health Association. As an active participant of the APHA Annual Meeting for many years we have seen growing interest and excitement generated around the need and desire to form a Men's Health Caucus and we are happy to see it come to fruition.
Health officials attending last week's World Health Assembly "failed to come to an agreement on a binding convention on stimulating research and development [R&D] focusing on the health problems of developing countries," BMJ reports.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.
Genevac reports customer paper describing development of a new evaporative methods for Mass Spec analysis replacing the traditional Solid Phase Extraction tech.
› Verified 5 days ago
| Entity Name | Arizona Acute Medical Services 1 Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154860674 PECOS PAC ID: 6204113970 Enrollment ID: O20170505001284 |
News Archive
Men's Health Network is pleased to announce the formation of a Men's Health Caucus in official relations with the American Public Health Association. As an active participant of the APHA Annual Meeting for many years we have seen growing interest and excitement generated around the need and desire to form a Men's Health Caucus and we are happy to see it come to fruition.
Health officials attending last week's World Health Assembly "failed to come to an agreement on a binding convention on stimulating research and development [R&D] focusing on the health problems of developing countries," BMJ reports.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.
Genevac reports customer paper describing development of a new evaporative methods for Mass Spec analysis replacing the traditional Solid Phase Extraction tech.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph Choi, 144 Green Valley Cir, Dresher, PA 19025-1515 Ph: (914) 338-3731 | Joseph Choi, 2000 W Bethany Home Rd, Phoenix, AZ 85015-2443 Ph: (602) 249-0212 |
News Archive
Men's Health Network is pleased to announce the formation of a Men's Health Caucus in official relations with the American Public Health Association. As an active participant of the APHA Annual Meeting for many years we have seen growing interest and excitement generated around the need and desire to form a Men's Health Caucus and we are happy to see it come to fruition.
Health officials attending last week's World Health Assembly "failed to come to an agreement on a binding convention on stimulating research and development [R&D] focusing on the health problems of developing countries," BMJ reports.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.
Genevac reports customer paper describing development of a new evaporative methods for Mass Spec analysis replacing the traditional Solid Phase Extraction tech.
› Verified 5 days ago
Dr. Joel Philip Betz, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2601 E Roosevelt St, Phoenix, AZ 85008 Phone: 602-344-5411 | |
Beth Marie Ranney, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 645 E Missouri Ave Ste 300, Phoenix, AZ 85012 Phone: 480-500-2540 | |
Dr. Carrie Lynn Cook, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111 E Mcdowell Rd, Phoenix, AZ 85006 Phone: 480-500-2540 Fax: 623-201-7954 | |
Diana M Bui, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-301-8000 | |
Dr. Diana Lynelle Dabell, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1300 N 12th St, Ste 301, Phoenix, AZ 85006 Phone: 602-839-6968 | |
Dr. Jason B Daniels, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5102 W Campbell Ave, Phoenix, AZ 85031 Phone: 623-848-5000 |